Rodrigo Dienstmann

Rodrigo Dienstmann is a medical oncologist with expertise in early drug development and molecularly-guided therapies. His research is focused on integrating biomarker data with clinical outcomes to boost precision cancer therapy. After graduating in Brazil and working as a medical oncologist in the public and private sectors, he moved to the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain, for training in phase I development of cancer drugs. He helped develop a molecular pre-screening strategy to match the genomic profile of each patient’s tumor to targeted agents. During his postgraduate training at the Molecular Pathology Laboratory of Massachusetts General Hospital, Boston, USA, he was responsible for standardized decision support and structured reports of next-generation sequencing tests of somatic cancer variants. He then assisted the Sage Bionetworks Computational Oncology team, Seattle, USA, in the application of big data analytics models for tumor subtyping, prognostic and predictive multi-omics markers. He then returned to the VHIO, Spain, as a clinical scientist to coordinate the Molecular Prescreening Program and Molecular Tumor Boards at the institution, as well as many real-world data studies and precision medicine trials. He also recently completed an Executive MBA program at ESADE Business School, with the aim of merging my scientific knowledge with management and leadership skills. Now, back in his home country, he is working as medical director of Oncoclínicas Precision Medicine and Big Data Initiatives, in São Paulo, Brazil.